Fluoroquinolones in pediatrics;Les fluoroquinolones en pédiatrie

Medecine et Maladies Infectieuses

Volumn 31, Issue 3, 2001, Pages 105-114

  Gendrel, D ^a   Moulin, F ^a   Sauve Martin H ^a   Raymond, J ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Children; Fluoroquinolones; Severe infections

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC THERAPY; CYSTIC FIBROSIS; DRUG EFFECT; HUMAN; NEWBORN INFECTION; REVIEW; SALMONELLOSIS; SHIGELLOSIS; STRAIN DIFFERENCE; TREATMENT INDICATION; URINARY TRACT INFECTION;

EID: 0035074524     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(01)00189-5     Document Type: Review

References (70)

1. Survey of unlicensed and off label drug use in paediatric wards in European countries
2. The use of fluoroquinolones in pediatrics: A reassessment
3. Trends in bacterial resistance to fluoroquinolones
4. New uses for new and old quinolones and the challenge of resistance
5. Emergence and dissemination of quinolone-resistant Escherichia coli in the community
6. Multicenter in vitro comparative study of fluoroquinolones in 25,129 gram-positive and gram-negative clinical isolates
7. Epidemiology of quinolone resistance: Europe and North and south America
8. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multiresistant. Salmonella typhi in India
9. Quinolone-resistant Salmonella typhi in Vietnam: Molecular basis if resistance and clinical response to treatment
10. Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-1997
11. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104
12. Quinolone resistance among Salmonella enterica from cattle, broilers, and swine in Denmark
13. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada Canadian Bacterial Surveillance Network
14. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children
15. Safety of ciprofloxacin in children: Worldwide clinical experience based on compassionate use Emphasis on joint evaluation
16. Ciprofloxacin in pediatrics: Worldwide clinical experience based on compassionate use-safety report
17. Ciprofloxacin in neonates and its possible adverse effect on the teeth
18. Side effects of pefloxacin in idiopathic nephrotic syndrome
19. Hypertension intracrânienne chez un nouveau-né traité par quinolones
20. Toxicité articulaire des quinolones
21. Fluoroquinolones toxicity profiles: A review focusing on newer agents
22. Quinolone arthropathy in animals versus children
23. Effects of ciprofloxacin and floxacin on adult human cartilage in vitro
24. Nalicixic acid in children: Retrospective matched controlled study for cartilage toxicity
25. Growth and joint symptoms in children treated with nalidixic acid
26. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin
27. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients
28. Retropective review of ciprofloxacin for the treatment of acute pulmonary exarcebation in the pediatric CF patient
29. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones
30. Achilles tendinitis induced by pefloxacin and other fluoroquinolone derivates
31. Pénétration et activité cellulaire des fluoroquinolones
32. Ciprofloxacin safety in pediatric population
33. Safety of long-term therapy with ciprofloxacin: Data analysis of controlled clinical trials and review
34. Enquête rétrospective sur l'utilisation des fluoroquinolones en pédiatrie
35. Use of fluoroquinolones in pediatrics: Consensus report of an International Society of Chemotherapy commission
36. Retropective review of ciprofloxacin for the treatment of acute pulmonary exarcebation in the pediatric CF patient
37. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations
38. Oral ciprofloxacin vs. intravenous ceftazidime plus obramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging
39. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytoprenic cancer patients with lymphomas and solid tumors
40. Norfloxacin in the prophylaxis of bacterial infections in neutropenic children
41. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients
42. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
43. Use of fluoroquinolones as prophylactic agents in patients with neutropenia
44. Ciprofloxacin in neonatal Enterobacter cloacae septicaemia
45. The treatment of neonatal meningitis due to gram negative bacilli with ciprofloxacina: Evidence of satisfactory penetration into the CSF
46. Use of ciprofloxacin in an infant with ventriculitis
47. Méningites néonatales: Place des fluoroquinolones
48. Cardiac toxicity of intravenous erythromycin lactobionate in preterm infants
49. Chronic otitis media treated topically with ciprofloxacin or tobramycin
50. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: Preliminary experience in 21 children
51. The antibiotic treatment of acute otitis media and sinusitis in children
52. Evaluation of norfloxacin in the pediatric field
53. Using quinolones in urinary tract infections in children
54. Ciprofloxacin for the treatment of severe typhoid fever in children
55. An open study of ciprofloxacin for the treatment of proven or suspected extra-intestinal salmonellosis in African children
56. Oral ciprofloxacin vs. Intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children
57. Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis
58. Eradication of convalescent salmonella carriage in children using two oral doses of Pefloxacin
59. Response to antimicrobial therapy for shigellosis in Thailand
60. Double-bind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children
61. One-dose treatment with pefloxacin for infection due to multidrug-resistant shigella dysenteriae type 1 in Burundi
62. Treatment of shigellosis: III. Comparison of one and two dose ciprofloxacin with standard 5 day treatment. A randomized, blinded trial
63. Short treatment with pefloxacin in madagascan children with shigellosis due to multiresistant organisms
64. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases
65. A randomized, controlled trial of oral or IV trovafloxacin vs. ceftriaxone in the treatment of epidemic meningococcal meningitis
66. Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis